Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA

NEW YORK, November 7, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Amgen, Inc. (NASDAQ: AMGN), Shire PLC (NASDAQ: SHPG) and HCA Holdings Inc. (NYSE: HCA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7775-100free.

--
Johnson & Johnson Research Reports
On November 4, 2014, Johnson & Johnson reported a clinical trial collaboration between its subsidiary Janssen Research & Development LLC, AstraZeneca, and Pharmacyclics, Inc. (Pharmacyclics) for assessing the efficacy and safety of the combination of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, with IMBRUVICA® (ibrutinib), an oral Bruton's tyrosine kinase inhibitor, co-developed and co-commercialized by Pharmacyclics and Janssen Biotech, Inc. The study will evaluate the combination as a treatment for patients with hematologic cancers including Diffuse Large B-Cell Lymphoma and Follicular Lymphoma, which are investigational uses for both compounds. Further, the Phase I part of the trial is expected to establish a recommended dose regimen for the combination of MEDI4736 and ibrutinib, and the Phase II will assess the safety and efficacy of the investigational combination. According to the terms of the agreement, Pharmacyclics will conduct the trial. The financial terms of the agreement have not been disclosed. The full research reports on Johnson & Johnson are available to download free of charge at:

http://www.analystsreview.com/Nov-07-2014/JNJ/report.pdf

--
Merck & Co., Inc. Research Reports
On October 27, 2014, Merck & Co., Inc. (Merck) announced the grant of Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) to KEYTRUDA® (pembrolizumab), the Company's anti-PD-1 therapy, for the treatment of patients with Epidermal Growth Factor Receptor (EGFR) mutation-negative, and Anaplastic Lymphoma Kinase (ALK) rearrangement-negative non-small cell lung cancer (NSCLC). The Company informed that this is the second Breakthrough Therapy Designation granted for KEYTRUDA. The Breakthrough Therapy Designation in advanced NSCLC is supported by data from the ongoing Phase 1b KEYNOTE-001 study. Merck added that the updated findings from the study were recently presented at the European Society of Medical Oncology (ESMO) 2014 Congress. The full research reports on Merck are available to download free of charge at:

http://www.analystsreview.com/Nov-07-2014/MRK/report.pdf

--
Amgen, Inc. Research Reports
On November 4, 2014, Amgen, Inc. (Amgen) announced the top-line results from the Phase 3 TRINOVA-1 trial in women with recurrent platinum-resistant ovarian cancer. The study evaluated trebananib plus paclitaxel versus placebo plus paclitaxel. The study did not demonstrate a statistically significant improvement in overall survival- the secondary endpoint of the study. Median overall survival was 19.3 months in the trebananib arm compared to 18.3 months in the control arm. The data will be submitted to a future medical conference and for publication. In the previously reported primary endpoint analysis, the data demonstrated a statistically significant difference in progression-free survival for trebananib. Sean E. Harper, M.D., Executive Vice President of Research and Development at Amgen, said, "While the overall survival results of the TRINOVA-1 study are disappointing, this study is the first of three Phase 3 trials designed to evaluate the safety and efficacy of trebananib in patients with ovarian cancer." The full research reports on Amgen are available to download free of charge at:

http://www.analystsreview.com/Nov-07-2014/AMGN/report.pdf

--
Shire PLC Research Reports
On November 3, 2014, Shire PLC (Shire) issued a press release in accordance with the Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1R. Shire informed that its issued ordinary share capital comprised 589.6 million ordinary shares of 5 pence each with voting rights and a further 9.0 million ordinary shares held in treasury, at the close of business on October 31, 2014. The Company stated that the total number of voting rights in the Company is 589.6 million. The full research reports on Shire are available to download free of charge at:

http://www.analystsreview.com/Nov-07-2014/SHPG/report.pdf

--
HCA Holdings Inc. Research Reports
On October 28, 2014, HCA Holdings Inc. (HCA) released its Q3 2014 and 9M 2014 financial results. The Company reported Q3 2014 revenues of $9.22 billion, up 9.0% YoY, surpassing sixteen Wall Street analysts' consensus revenue estimate of $9.12 billion for the quarter. The Company's Q3 2014 net income attributable to HCA came in at $518 million or $1.16 per diluted share, compared to net income of $365 million or $0.79 million per diluted share in Q3 2013. The Company's Q3 2014 adjusted diluted EPS stood at $1.18, surpassing average EPS estimate of $1.05 for the quarter by Thomson Reuters. The Company reported 9M 2014 revenues of $27.3 billion, up 7.6% YoY and net income attributable to HCA of $1.3 billion, up 19.1% YoY. For full-year 2014, the Company expects revenues in the range of $36.5 - $37 billion and adjusted diluted EPS in the range of $4.40 - $4.60. The Company informed that its Board authorized a share repurchase program for up to $1 billion of the Company's outstanding common stock. The full research reports on HCA are available to download free of charge at:

http://www.analystsreview.com/Nov-07-2014/HCA/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review